191 related articles for article (PubMed ID: 12876631)
1. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Brouwers GJ; Leebeek FW; Tanck MW; Wouter Jukema J; Kluft C; de Maat MP
Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
[TBL] [Abstract][Full Text] [Related]
2. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI).
Morange PE; Juhan-Vague I; Scarabin PY; Alessi MC; Luc G; Arveiler D; Ferrieres J; Amouyel P; Evans A; Ducimetiere P;
Thromb Haemost; 2003 Mar; 89(3):554-60. PubMed ID: 12624641
[TBL] [Abstract][Full Text] [Related]
3. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
4. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Juhan-Vague I; Morange PE; Aubert H; Henry M; Aillaud MF; Alessi MC; Samnegård A; Hawe E; Yudkin J; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):867-73. PubMed ID: 12006404
[TBL] [Abstract][Full Text] [Related]
5. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
7. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions.
Segev A; Hegele RA; Lau HK; Sparkes JD; Teitel JM; Chisholm RJ; Strauss BH
Thromb Res; 2004; 114(2):137-41. PubMed ID: 15306156
[TBL] [Abstract][Full Text] [Related]
8. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
Morange PE; Tregouet DA; Frere C; Luc G; Arveiler D; Ferrieres J; Amouyel P; Evans A; Ducimetiere P; Cambien F; Tiret L; Juhan-Vague I;
J Thromb Haemost; 2005 Jul; 3(7):1503-10. PubMed ID: 15978108
[TBL] [Abstract][Full Text] [Related]
9. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.
Henry M; Aubert H; Morange PE; Nanni I; Alessi MC; Tiret L; Juhan-Vague I
Blood; 2001 Apr; 97(7):2053-8. PubMed ID: 11264171
[TBL] [Abstract][Full Text] [Related]
10. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
Santos IR; Fernandes AP; Carvalho MG; Sousa MO; Ferreira CN; Gomes KB
Clin Chim Acta; 2014 Jun; 433():76-83. PubMed ID: 24631134
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
12. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Kozian DH; Lorenz M; März W; Cousin E; Mace S; Deleuze JF
Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
[TBL] [Abstract][Full Text] [Related]
13. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
Frère C; Morange PE; Saut N; Tregouet DA; Grosley M; Beltran J; Juhan-Vague I; Alessi MC
Thromb Haemost; 2005 Aug; 94(2):373-9. PubMed ID: 16113828
[TBL] [Abstract][Full Text] [Related]
14. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Meltzer ME; Doggen CJ; de Groot PG; Meijers JC; Rosendaal FR; Lisman T
Haematologica; 2009 Jun; 94(6):811-8. PubMed ID: 19377074
[TBL] [Abstract][Full Text] [Related]
15. A new functional assay of thrombin activatable fibrinolysis inhibitor.
Guimarães AH; Bertina RM; Rijken DC
J Thromb Haemost; 2005 Jun; 3(6):1284-92. PubMed ID: 15946219
[TBL] [Abstract][Full Text] [Related]
16. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
Guimarães AH; van Tilburg NH; Vos HL; Bertina RM; Rijken DC
Br J Haematol; 2004 Mar; 124(5):659-65. PubMed ID: 14871254
[TBL] [Abstract][Full Text] [Related]
17. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Kamal HM; Ahmed AS; Fawzy MS; Mohamed FA; Elbaz AA
Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
[TBL] [Abstract][Full Text] [Related]
18. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms.
Trégouet DA; Aubert H; Henry M; Morange P; Visvikis S; Juhan-Vague I; Tiret L
Hum Genet; 2001 Aug; 109(2):191-7. PubMed ID: 11511925
[TBL] [Abstract][Full Text] [Related]
19. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
de Bruijne EL; Gils A; Guimarães AH; Dippel DW; Deckers JW; van den Meiracker AH; Poldermans D; Rijken DC; Declerck PJ; de Maat MP; Leebeek FW
J Thromb Haemost; 2009 Jun; 7(6):919-27. PubMed ID: 19323787
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
